Collaboration Agreement WITH PACS2 Research Foundation signed

Recently we've entered research collaboration with the PACS2 Research Foundation, which unites patients affected by ultra-rare genetic disease caused by autosomal dominant mutation in PACS2 gene that leads to developmental and epileptic encephalopathy (DEEs).

At the Nencki Institute the study will be conducted by our MitoLab team as well as by the team from the Laboratory of Cell Signalling and Metabolic Disorders headed by Prof. Agnieszka Dobrzyn.

A coordinated by me this collaborative research will contribute to a better understanding of the pathomechanism of this disease by filling the knowledge gaps regarding the impact of mutation in PACS2 gene on cellular metabolism.

Collaboration Agreement WITH NBIA Association Poland signed

Recently we've entered research collaboration with NBIA Association Poland, which unites patients affected by a rare genetic disease characterized by excessive brain iron accumulation (NBIA - neurodegeneration with brain iron accumulation).

The research that will be conducted in our Laboratory (in a close collaboration with the Laboratory of Cell Signalling and Metabolic Disorders headed by Prof. Agnieszka Dobrzyn also from Nencki Institute) will contribute to a better understanding of the pathomechanisms of NBIA disease most likely related to the alterations in lipid metabolism and mitochondrial dysfunction.

The tiger head present in the NBIA Poland Association's logo shows the characteristic - 

"Tiger's Eye" visible in the MRI image of children diagnosed with this disease (especially the NBIA-PKAN type).

COLLABORATION AGREEMENT WITH THERESON S.r.l. SIGNED

It is a great pleasure to announce that we've entered a research collaboration with THERESON a company focusing on therapeutic magnetic resonance.

Our Laboratory will support THERESON in the effort to expand the spectrum of applications of TMR® Therapeutic Magnetic Resonance, beyond wound care management.

THERESON is an Italian, medical device company, dedicated to the treatment of Vascular pathologies, related to Microcirculation, Orthopedic and Degenerative diseases. Their first medical device DIAPASON®, utilising TMR® Therapeutic Magnetic Resonance in wound care management, was launched to the market in 2017. The company is dedicated to clinical and scientific research and aims to demonstrate the effectiveness of the treatment through rigorously gathered experimental data.